Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
32 hedge funds and large institutions have $19.4M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
3% less funds holding
Funds holding: 33 → 32 (-1)
13% less capital invested
Capital invested by funds: $22.3M → $19.4M (-$2.94M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$200K |
| 2 |
Mariner
Overland Park,
Kansas
|
+$154K |
| 3 |
ACA
Apis Capital Advisors
New York
|
+$90.7K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$21.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$578K |
| 2 |
Renaissance Technologies
New York
|
-$187K |
| 3 |
Two Sigma Investments
New York
|
-$174K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$168K |
| 5 |
D.E. Shaw & Co
New York
|
-$120K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $13K | -$1.89K | -167 | -12% |
|
|
LC
27
Lindbrook Capital
Calabasas,
California
| $5K | – | – | – |
|
|
SWM
28
Spire Wealth Management
Mclean,
Virginia
| $5K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $4K | -$10.6K | -935 | -68% |
|
|
ARMC
30
American Research & Management Company
Marion,
Massachusetts
| $3K | – | – | – |
|
|
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $1.94K | – | – | – |
|
32
National Bank of Canada
Montreal,
Quebec, Canada
| $1K | – | – | – |
|
|
33
D.E. Shaw & Co
New York
| – | -$120K | -10,044 | Closed |
|
34
Bank of America
Charlotte,
North Carolina
| – | -$5K | -384 | Closed |
|
|
CA
35
CoreCap Advisors
Southfield,
Michigan
| – | -$3K | -266 | Closed |
|
OPNT Hedge Fund Activity: Q3 2022 in Review
32 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q3 2022, worth a combined $19.4M — down 13% from $22.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OPNT and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 10 added.
The largest buyer was Mesirow Financial Investment Management, opening a new position worth an estimated $200K. The largest seller was Two Sigma Advisers, cutting an estimated $578K.
- 32 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q3 2022, down from 33 in Q2 2022.
- Funds reported $19.4M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 13% quarter-over-quarter.
- 3 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of -1 holder.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Mesirow Financial Investment Management, an estimated $200K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Two Sigma Advisers, an estimated $578K sold.
Based on aggregated 13F filings for Q3 2022.